HSK47388 vs icotrokinra

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-23 receptor · full Psoriasis pipeline

HSK47388

Developed by Haisco Pharmaceutical Group

Phase 2 in Psoriasispeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07158268 (registry estimate)

No aligned efficacy figure on record for this race.

icotrokinra · Icotyde

Marketed by Johnson & Johnson and partners

Approved in PsoriasisOral peptide (IL-23R antagonist)
Reliable signal

NCT06095115 · Phase 3 · active, not recruiting

Participants were randomly assigned 2:1 to the drug or placebo, with participants and investigators masked, and 684 people enrolled. Both co-primary endpoints, an IGA score of 0 or 1 with at least a 2-grade improvement and PASI 90 at Week 16, are validated clinical measures of skin disease, and both were met with high statistical significance (p<0.001).

Reported efficacy

Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16; Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16 (Week 16): JNJ-77242113 200 mg 64.7% (met)

Result source: NCT06095115

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHSK47388icotrokinra
PASI 75—Not reported65.1% vs 9.3%+55.8 vs placebo100 mg QD · wk 16 · n 43NCT05223868
6 other results
  • 78.6% vs 9.3% 100 mg BID · wk 16 · n 42 · Phase 2 · primary NCT05223868
  • 58.1% vs 9.3% 50 mg QD · wk 16 · n 43 · Phase 2 · primary NCT05223868
  • 73.5% vs 4.2% 50 mg QD · wk 16 · n 34 · Phase 2 · primary NCT05357755
  • 37.2% vs 9.3% 25 mg QD · wk 16 · n 43 · Phase 2 · primary NCT05223868
  • 51.2% vs 9.3% 25 mg BID · wk 16 · n 41 · Phase 2 · primary NCT05223868
  • 41.9% vs 4.2% 10 mg QD · wk 16 · n 31 · Phase 2 · primary NCT05357755
PASI 90—Not reported46.5% vs 2.3%+44.2 vs placebo100 mg QD · wk 16 · n 43NCT05223868
6 other results
  • 59.5% vs 2.3% 100 mg BID · wk 16 · n 42 · Phase 2 · secondary NCT05223868
  • 51.2% vs 2.3% 50 mg QD · wk 16 · n 43 · Phase 2 · secondary NCT05223868
  • 52.9% vs 0% 50 mg QD · wk 16 · n 34 · Phase 2 · secondary NCT05357755
  • 25.6% vs 2.3% 25 mg QD · wk 16 · n 43 · Phase 2 · secondary NCT05223868
  • 26.8% vs 2.3% 25 mg BID · wk 16 · n 41 · Phase 2 · secondary NCT05223868
  • 25.8% vs 0% 10 mg QD · wk 16 · n 31 · Phase 2 · secondary NCT05357755
PASI 100—Not reported23.3% vs 0%+23.3 vs placebo100 mg QD · wk 16 · n 43NCT05223868
6 other results
  • 40.5% vs 0% 100 mg BID · wk 16 · n 42 · Phase 2 · secondary NCT05223868
  • 25.6% vs 0% 50 mg QD · wk 16 · n 43 · Phase 2 · secondary NCT05223868
  • 23.5% vs 0% 50 mg QD · wk 16 · n 34 · Phase 2 · secondary NCT05357755
  • 11.6% vs 0% 25 mg QD · wk 16 · n 43 · Phase 2 · secondary NCT05223868
  • 9.8% vs 0% 25 mg BID · wk 16 · n 41 · Phase 2 · secondary NCT05223868
  • 9.7% vs 0% 10 mg QD · wk 16 · n 31 · Phase 2 · secondary NCT05357755
sPGA 0/1—Not reported—Trial running · NCT06295692
DLQI, change—Not reported—Trial running · NCT06295692

PASI 75

HSK47388
—Not reported
icotrokinra
65.1% vs 9.3%+55.8 vs placebo100 mg QD · wk 16 · n 43NCT05223868
6 other results
  • 78.6% vs 9.3% 100 mg BID · wk 16 · n 42 · Phase 2 · primary NCT05223868
  • 58.1% vs 9.3% 50 mg QD · wk 16 · n 43 · Phase 2 · primary NCT05223868
  • 73.5% vs 4.2% 50 mg QD · wk 16 · n 34 · Phase 2 · primary NCT05357755
  • 37.2% vs 9.3% 25 mg QD · wk 16 · n 43 · Phase 2 · primary NCT05223868
  • 51.2% vs 9.3% 25 mg BID · wk 16 · n 41 · Phase 2 · primary NCT05223868
  • 41.9% vs 4.2% 10 mg QD · wk 16 · n 31 · Phase 2 · primary NCT05357755

PASI 90

HSK47388
—Not reported
icotrokinra
46.5% vs 2.3%+44.2 vs placebo100 mg QD · wk 16 · n 43NCT05223868
6 other results
  • 59.5% vs 2.3% 100 mg BID · wk 16 · n 42 · Phase 2 · secondary NCT05223868
  • 51.2% vs 2.3% 50 mg QD · wk 16 · n 43 · Phase 2 · secondary NCT05223868
  • 52.9% vs 0% 50 mg QD · wk 16 · n 34 · Phase 2 · secondary NCT05357755
  • 25.6% vs 2.3% 25 mg QD · wk 16 · n 43 · Phase 2 · secondary NCT05223868
  • 26.8% vs 2.3% 25 mg BID · wk 16 · n 41 · Phase 2 · secondary NCT05223868
  • 25.8% vs 0% 10 mg QD · wk 16 · n 31 · Phase 2 · secondary NCT05357755

PASI 100

HSK47388
—Not reported
icotrokinra
23.3% vs 0%+23.3 vs placebo100 mg QD · wk 16 · n 43NCT05223868
6 other results
  • 40.5% vs 0% 100 mg BID · wk 16 · n 42 · Phase 2 · secondary NCT05223868
  • 25.6% vs 0% 50 mg QD · wk 16 · n 43 · Phase 2 · secondary NCT05223868
  • 23.5% vs 0% 50 mg QD · wk 16 · n 34 · Phase 2 · secondary NCT05357755
  • 11.6% vs 0% 25 mg QD · wk 16 · n 43 · Phase 2 · secondary NCT05223868
  • 9.8% vs 0% 25 mg BID · wk 16 · n 41 · Phase 2 · secondary NCT05223868
  • 9.7% vs 0% 10 mg QD · wk 16 · n 31 · Phase 2 · secondary NCT05357755

sPGA 0/1

HSK47388
—Not reported
icotrokinra
—Trial running · NCT06295692

DLQI, change

HSK47388
—Not reported
icotrokinra
—Trial running · NCT06295692
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HSK47388: no structured comparison results are available for Psoriasis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. HSK47388: 0 of 4 rows · icotrokinra: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricicotrokinra
Dropout rate
4.2%200 mga
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
show 17 more results
—200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
—200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
—200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
—200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
9.5%100 mg BID
NCT05223868 · Phase 2
4.7%100 mg QD
NCT05223868 · Phase 2
7%50 mg QD
NCT05223868 · Phase 2
2.4%25 mg BID
NCT05223868 · Phase 2
16.3%25 mg QD
NCT05223868 · Phase 2
7.9%100 mg BID
NCT05364554 · Phase 2 · registry result, not featured evidence
17.5%100 mg QD
NCT05364554 · Phase 2 · registry result, not featured evidence
17.1%100 mg QD
NCT05364554 · Phase 2 · registry result, not featured evidence
15.4%50 mg QD
NCT05364554 · Phase 2 · registry result, not featured evidence
25%25 mg BID
NCT05364554 · Phase 2 · registry result, not featured evidence
22.9%25 mg QD
NCT05364554 · Phase 2 · registry result, not featured evidence
5.9%50 mg QD
NCT05357755 · Phase 2 · registry result, not featured evidence
29%10 mg QD
NCT05357755 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1.1%200 mga
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
show 17 more results
—200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
—200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
—200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
—200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
—100 mg BID
NCT05223868 · Phase 2
—100 mg QD
NCT05223868 · Phase 2
—50 mg QD
NCT05223868 · Phase 2
—25 mg BID
NCT05223868 · Phase 2
—25 mg QD
NCT05223868 · Phase 2
—100 mg BID
NCT05364554 · Phase 2 · registry result, not featured evidence
—100 mg QD
NCT05364554 · Phase 2 · registry result, not featured evidence
—100 mg QD
NCT05364554 · Phase 2 · registry result, not featured evidence
—50 mg QD
NCT05364554 · Phase 2 · registry result, not featured evidence
—25 mg BID
NCT05364554 · Phase 2 · registry result, not featured evidence
—25 mg QD
NCT05364554 · Phase 2 · registry result, not featured evidence
—50 mg QD
NCT05357755 · Phase 2 · registry result, not featured evidence
—10 mg QD
NCT05357755 · Phase 2 · registry result, not featured evidence
Serious AEs
—200 mga
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
show 17 more results
1.1%200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
1.3%200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
2.1%200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
1.8%200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
0%100 mg BID
NCT05223868 · Phase 2
4.7%100 mg QD
NCT05223868 · Phase 2
2.3%50 mg QD
NCT05223868 · Phase 2
0%25 mg BID
NCT05223868 · Phase 2
0%25 mg QD
NCT05223868 · Phase 2
2.6%100 mg BID
NCT05364554 · Phase 2 · registry result, not featured evidence
5%100 mg QD
NCT05364554 · Phase 2 · registry result, not featured evidence
2.9%100 mg QD
NCT05364554 · Phase 2 · registry result, not featured evidence
5.1%50 mg QD
NCT05364554 · Phase 2 · registry result, not featured evidence
7.5%25 mg BID
NCT05364554 · Phase 2 · registry result, not featured evidence
0%25 mg QD
NCT05364554 · Phase 2 · registry result, not featured evidence
5.9%50 mg QD
NCT05357755 · Phase 2 · registry result, not featured evidence
0%10 mg QD
NCT05357755 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
200 mga
nasopharyngitis 2.5% (placebo 6.6%)
upper respiratory tract infection 1.4% (placebo 7%)
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
show 16 more results
200 mg
nasopharyngitis 6.8% (placebo 6.6%)
upper respiratory tract infection 6.6% (placebo 7%)
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
200 mg
nasopharyngitis 14.6% (placebo 6.6%)
upper respiratory tract infection 8.3% (placebo 7%)
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
200 mg
nasopharyngitis 12.5% (placebo 6.6%)
upper respiratory tract infection 5.4% (placebo 7%)
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
100 mg BID
covid-19 9.5% (placebo 11.6%)
nasopharyngitis 4.8% (placebo 4.7%)
upper respiratory tract infection 4.8% (placebo 2.3%)
NCT05223868 · Phase 2
100 mg QD
cough 7% (placebo 0%)
headache 7% (placebo 2.3%)
covid-19 4.7% (placebo 11.6%)
NCT05223868 · Phase 2
50 mg QD
nasopharyngitis 18.6% (placebo 4.7%)
diarrhoea 9.3% (placebo 2.3%)
covid-19 7% (placebo 11.6%)
NCT05223868 · Phase 2
25 mg BID
covid-19 19.5% (placebo 11.6%)
nasopharyngitis 7.3% (placebo 4.7%)
diarrhoea 4.9% (placebo 2.3%)
NCT05223868 · Phase 2
25 mg QD
covid-19 11.6% (placebo 11.6%)
upper respiratory tract infection 7% (placebo 2.3%)
diarrhoea 4.7% (placebo 2.3%)
NCT05223868 · Phase 2
100 mg BID
nasopharyngitis 13.2%
upper respiratory tract infection 10.5%
covid-19 7.9%
NCT05364554 · Phase 2 · registry result, not featured evidence
100 mg QD
nasopharyngitis 27.5%
headache 7.5%
arthralgia 5%
NCT05364554 · Phase 2 · registry result, not featured evidence
100 mg QD
nasopharyngitis 25.7%
upper respiratory tract infection 11.4%
alanine aminotransferase increased 5.7%
NCT05364554 · Phase 2 · registry result, not featured evidence
50 mg QD
nasopharyngitis 17.9%
bronchitis 7.7%
covid-19 7.7%
NCT05364554 · Phase 2 · registry result, not featured evidence
25 mg BID
nasopharyngitis 15%
headache 7.5%
influenza 7.5%
NCT05364554 · Phase 2 · registry result, not featured evidence
25 mg QD
upper respiratory tract infection 17.1%
nasopharyngitis 8.6%
headache 5.7%
NCT05364554 · Phase 2 · registry result, not featured evidence
50 mg QD
covid-19 8.8% (placebo 0%)
back pain 5.9% (placebo 0%)
headache 5.9% (placebo 0%)
NCT05357755 · Phase 2 · registry result, not featured evidence
10 mg QD
alanine aminotransferase increased 6.5% (placebo 0%)
aspartate aminotransferase increased 6.5% (placebo 0%)
blood glucose increased 6.5% (placebo 0%)
NCT05357755 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 13 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

icotrokinra

IGA 0/1 64.7% (n=456) @ 16wk200 mg
responder rate · % of participants
No placebo or comparator arm
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
show 1 more result
81.8% (n=44) @ 52wk200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
PASI 90 49.6% (n=456) @ 16wk200 mg
responder rate · % of participants
No placebo or comparator arm
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
show 2 more results
21.5% (n=456) @ 8wk200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
86.4% (n=44) @ 52wk200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
IGA 0 33.3% (n=456) @ 16wk200 mg
responder rate · % of participants
No placebo or comparator arm
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
PASI 75 14.9% (n=456) @ 4wk200 mg
responder rate · % of participants
No placebo or comparator arm
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
show 2 more results
69.1% (n=456) @ 16wk200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
95.5% (n=44) @ 52wk200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
PASI 100 27% (n=456) @ 16wk200 mg
responder rate · % of participants
No placebo or comparator arm
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
PASI 75 89.4% (n=161) vs 29.5% (n=166) placebo @ 52wk200 mg
responder rate · % of participants
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
show 7 more results
65.1% (n=43) vs 9.3% (n=43) placebo @ 16wk100 mg QD
NCT05223868 · Phase 2
78.6% (n=42) vs 9.3% (n=43) placebo @ 16wk100 mg BID
NCT05223868 · Phase 2
58.1% (n=43) vs 9.3% (n=43) placebo @ 16wk50 mg QD
NCT05223868 · Phase 2
73.5% (n=34) vs 4.2% (n=24) placebo @ 16wk50 mg QD
NCT05357755 · Phase 2 · registry result, not featured evidence
37.2% (n=43) vs 9.3% (n=43) placebo @ 16wk25 mg QD
NCT05223868 · Phase 2
51.2% (n=41) vs 9.3% (n=43) placebo @ 16wk25 mg BID
NCT05223868 · Phase 2
41.9% (n=31) vs 4.2% (n=24) placebo @ 16wk10 mg QD
NCT05357755 · Phase 2 · registry result, not featured evidence
PASI 90 84.4% (n=128) vs 20.9% (n=129) placebo @ 52wk200 mg
responder rate · % of participants
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
show 7 more results
46.5% (n=43) vs 2.3% (n=43) placebo @ 16wk100 mg QD
NCT05223868 · Phase 2
59.5% (n=42) vs 2.3% (n=43) placebo @ 16wk100 mg BID
NCT05223868 · Phase 2
51.2% (n=43) vs 2.3% (n=43) placebo @ 16wk50 mg QD
NCT05223868 · Phase 2
52.9% (n=34) vs 0% (n=24) placebo @ 16wk50 mg QD
NCT05357755 · Phase 2 · registry result, not featured evidence
25.6% (n=43) vs 2.3% (n=43) placebo @ 16wk25 mg QD
NCT05223868 · Phase 2
26.8% (n=41) vs 2.3% (n=43) placebo @ 16wk25 mg BID
NCT05223868 · Phase 2
25.8% (n=31) vs 0% (n=24) placebo @ 16wk10 mg QD
NCT05357755 · Phase 2 · registry result, not featured evidence
Duration of Response NA vs 3.9 placebo months200 mg
time to event · months
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
show 2 more results
NA vs 2.33 placebo months200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
NA vs 2.33 placebo months200 mg
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
PASI -78.7% (n=439) @ 16wk200 mg
percent change · % of baseline
No placebo or comparator arm
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
IGA 0/1 82% (n=150) vs 23.3% (n=150) placebo @ 52wk200 mg
responder rate · % of participants
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
show 8 more results
56.7% (n=208) vs 5.8% (n=103) placebo @ 16wk200 mg
NCT06095102 · Phase 3 · monotherapy · Psoriasis · phase 3
62.8% (n=43) vs 11.6% (n=43) placebo @ 16wk100 mg QD
NCT05223868 · Phase 2
64.3% (n=42) vs 11.6% (n=43) placebo @ 16wk100 mg BID
NCT05223868 · Phase 2
58.1% (n=43) vs 11.6% (n=43) placebo @ 16wk50 mg QD
NCT05223868 · Phase 2
73.5% (n=34) vs 4.2% (n=24) placebo @ 16wk50 mg QD
NCT05357755 · Phase 2 · registry result, not featured evidence
39.5% (n=43) vs 11.6% (n=43) placebo @ 16wk25 mg QD
NCT05223868 · Phase 2
51.2% (n=41) vs 11.6% (n=43) placebo @ 16wk25 mg BID
NCT05223868 · Phase 2
41.9% (n=31) vs 4.2% (n=24) placebo @ 16wk10 mg QD
NCT05357755 · Phase 2 · registry result, not featured evidence
IGA 0 70.2% (n=84) vs 10.8% (n=93) placebo @ 52wk200 mg
responder rate · % of participants
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
show 7 more results
27.9% (n=43) vs 0% (n=43) placebo @ 16wk100 mg QD
NCT05223868 · Phase 2
45.2% (n=42) vs 0% (n=43) placebo @ 16wk100 mg BID
NCT05223868 · Phase 2
34.9% (n=43) vs 0% (n=43) placebo @ 16wk50 mg QD
NCT05223868 · Phase 2
29.4% (n=34) vs 0% (n=24) placebo @ 16wk50 mg QD
NCT05357755 · Phase 2 · registry result, not featured evidence
16.3% (n=43) vs 0% (n=43) placebo @ 16wk25 mg QD
NCT05223868 · Phase 2
14.6% (n=41) vs 0% (n=43) placebo @ 16wk25 mg BID
NCT05223868 · Phase 2
12.9% (n=31) vs 0% (n=24) placebo @ 16wk10 mg QD
NCT05357755 · Phase 2 · registry result, not featured evidence
PASI 100 74% (n=73) vs 9.8% (n=82) placebo @ 52wk200 mg
responder rate · % of participants
NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3
show 7 more results
23.3% (n=43) vs 0% (n=43) placebo @ 16wk100 mg QD
NCT05223868 · Phase 2
40.5% (n=42) vs 0% (n=43) placebo @ 16wk100 mg BID
NCT05223868 · Phase 2
25.6% (n=43) vs 0% (n=43) placebo @ 16wk50 mg QD
NCT05223868 · Phase 2
23.5% (n=34) vs 0% (n=24) placebo @ 16wk50 mg QD
NCT05357755 · Phase 2 · registry result, not featured evidence
11.6% (n=43) vs 0% (n=43) placebo @ 16wk25 mg QD
NCT05223868 · Phase 2
9.8% (n=41) vs 0% (n=43) placebo @ 16wk25 mg BID
NCT05223868 · Phase 2
9.7% (n=31) vs 0% (n=24) placebo @ 16wk10 mg QD
NCT05357755 · Phase 2 · registry result, not featured evidence

+ 16 further endpoints in the CSV export.

Ulcerative Colitis

Shared mechanism: IL-23 receptor · full Ulcerative Colitis pipeline

HSK47388

Developed by Haisco Pharmaceutical Group

Phase 2 in Ulcerative Colitispeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: October 2027 · NCT07335055 (registry estimate)

No aligned efficacy figure on record for this race.

icotrokinra · Icotyde

Marketed by Johnson & Johnson and partners

Phase 3 in Ulcerative ColitisOral peptide (IL-23R antagonist)
Reliable signal

NCT06049017 · Phase 2 · completed

This randomized, double-blind, placebo-controlled trial enrolled 252 patients and measured clinical response, based on a validated ulcerative colitis disease-activity score, at week 12. The highest icotrokinra dose achieved a clinical response in 63.5% of patients versus 27% on placebo, a highly statistically significant difference.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: January 2028 · NCT07196748 (registry estimate)

Reported efficacy

Percentage of Participants with Clinical Response at Week 12: Primary endpoint clinical response at Week 12: 63.5% with the highest icotrokinra dose vs 27% with placebo (p<0.001) (met)

Result source: NCT06049017

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHSK47388icotrokinra
Clinical remission (induction)—Not reported—Trial running · NCT07196748
Clinical remission (maintenance)—Not reported—Trial running · NCT07196748
Clinical response (induction)—Not reported—Trial running · NCT07196748
Endoscopic improvement (induction)—Not reported—Trial running · NCT07196748
Corticosteroid-free remission (maintenance)—Not reported—Trial running · NCT07196748

Clinical remission (induction)

HSK47388
—Not reported
icotrokinra
—Trial running · NCT07196748

Clinical remission (maintenance)

HSK47388
—Not reported
icotrokinra
—Trial running · NCT07196748

Clinical response (induction)

HSK47388
—Not reported
icotrokinra
—Trial running · NCT07196748

Endoscopic improvement (induction)

HSK47388
—Not reported
icotrokinra
—Trial running · NCT07196748

Corticosteroid-free remission (maintenance)

HSK47388
—Not reported
icotrokinra
—Trial running · NCT07196748
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HSK47388: no structured comparison results are available for Ulcerative Colitis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

icotrokinra
Primary endpoint clinical response at Week 12: 63.5% with the highest icotrokinra dose vs 27% with placebo (p<0.001) NCT06049017 · Phase 2 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HSK47388's landscape · icotrokinra's landscape